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Summary
Background Primaquine is the only available drug that clears mature Plasmodium falciparum gametocytes in infected 
human hosts, thereby preventing transmission of malaria to mosquitoes. However, concerns about dose-dependent 
haemolysis in people with glucose-6-phosphate dehydrogenase (G6PD) deﬁ ciencies have limited its use. We assessed 
the dose-response association of single-dose primaquine for gametocyte clearance and for safety in P falciparum 
malaria.
Methods We undertook this randomised, double-blind, placebo-controlled trial with four parallel groups in Jinja 
district, eastern Uganda. We randomly allocated Ugandan children aged 1–10 years with uncomplicated falciparum 
malaria and normal G6PD enzyme function to receive artemether–lumefantrine, combined with either placebo or 
with 0∙1 mg/kg, 0∙4 mg/kg, or 0∙75 mg/kg (WHO reference dose) primaquine base. Randomisation was done with 
computer-generated four-digit treatment assignment codes allocated to random dose groups in block sizes of 16. 
Study staﬀ  who provided care or assessed outcomes and the participants remained masked to the intervention group 
after assignment. The primary eﬃ  cacy endpoint was the non-inferiority of the mean duration of gametocyte carriage 
in the test doses compared with the reference group of 0∙75 mg primaquine per kg, with a non-inferiority margin of 
2·5 days. The primary safety endpoint was the superiority of the arithmetic mean maximum decrease in haemoglobin 
concentration from enrolment to day 28 of follow-up in the primaquine treatment groups compared with placebo, 
with use of signiﬁ cance testing of pairwise comparisons with a cutoﬀ  of p=0·05. The trial is registered with 
ClinicalTrials.gov, number NCT01365598.
Findings We randomly allocated 468 participants to receive artemether–lumefantrine combined with placebo 
(119 children) or with 0∙1 mg/kg (116), 0∙4 mg/kg (116), or 0∙75 mg/kg (117) primaquine base. The mean duration of 
gametocyte carriage was 6∙6 days (95% CI 5∙3–7∙8) in the 0∙75 mg/kg reference group, 6·3 days (5·1–7·5) in the 
0∙4 mg/kg primaquine group (p=0∙74), 8·0 days (6∙6–9∙4) in the 0∙1 mg/kg primaquine group (p=0∙14), and 12∙4 days 
(9∙9–15∙0) in the placebo group (p<0∙0001). No children showed evidence of treatment-related haemolysis, and the 
mean maximum decrease in haemoglobin concentration was not associated with the dose of primaquine received—it 
did not diﬀ er signiﬁ cantly compared with placebo (10·7 g/L, SD 11·1) in the 0∙1 mg/kg (11·4 g/L, 9·4; p=0∙61), 
0∙4 mg/kg (11·3 g/L, 10·0; p=0∙67), or 0∙75 mg/kg (12·7 g/L, 8·2; p=0∙11) primaquine groups.
Interpretation We conclude that 0∙4 mg/kg primaquine has similar gametocytocidal eﬃ  cacy to the reference 
0∙75 mg/kg primaquine dose, but a dose of 0∙1 mg/kg was inconclusive for non-inferiority. Our ﬁ ndings call for the 
prioritisation of further trials into the eﬃ  cacy and safety of doses of primaquine between 0∙1 mg/kg and 0∙4 mg/kg 
(including the dose of 0∙25 mg/kg recently recommended by WHO), in view of the potential for widespread use of 
the drug to block malaria transmission.
Funding Wellcome Trust and the Bill & Melinda Gates Foundation. 
Introduction
Eﬀ ective drug therapy is a key component of malaria 
control and elimination strategies to reduce both 
morbidity from the disease and onward transmission to 
mosquitoes.1 Artemisinin combination therapy (ACT), 
the ﬁ rst-line treatment in sub-Saharan Africa, achieves 
excellent cure rates for Plasmodium falciparum through 
rapid clearance of the asexual stages of the parasite. As a 
consequence, ACT reduces the production of malaria 
transmission stages—gametocytes—and thereby restricts 
transmission potential.2 However, onward malaria trans-
mission is not completely prevented because of the 
inadequate eﬀ ect of artemisinins and their partner drugs 
against mature gametocytes. If mature gametocytes are 
present before treatment, they persist after ACT, often at 
concentrations below the threshold for detection by 
conventional microscopy,3 and can allow onward malaria 
transmission for up to 14 days after treatment.3–6 
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Primaquine, an 8-aminoquinoline, is the only available 
drug with established activity against mature 
gametocytes. It clears circulating gametocytes that persist 
after ACT, thereby reducing the duration of gametocyte 
carriage,7–12 and renders most patients free of gametocytes 
by day 14 after initiation of ACT–primaquine treat-
ment.7–9,12 Primaquine reduces the transmission of 
malaria to mosquitoes—an eﬀ ect that might precede the 
clearance of gametocytes.13,14 The transmission-blocking 
properties of primaquine have been reviewed in detail.15 
WHO has recommended one dose of primaquine in 
addition to ACTs for use in two scenarios: for malaria 
elimination programmes, and to stop the spread of 
emerging artemisinin resistance.16 Primaquine is 
recommended for use in ﬁ rst-line antimalarial treatment 
in many countries.17 
Despite these recommendations, primaquine is often 
not used because of concerns about its haemolytic eﬀ ect 
in people with glucose-6-phosphate dehydrogenase 
(G6PD) deﬁ ciency. Primaquine-induced haemolysis can 
occur after one dose of the drug18 and is dose dependent.19 
Because doses of primaquine lower than the WHO-
recommended dose can be equally eﬃ  cacious at 
clearance of P falciparum gametocytes,15 dose optimisation 
for ACT–primaquine is needed.
No formal randomised controlled trials have been done 
to characterise the dose-response relation of primaquine 
for P falciparum gametocyte clearance. We aimed to 
assess the eﬃ  cacy of reduced doses of primaquine for 
non-inferiority to the WHO reference dose of 0∙75 mg 
primaquine base per kg that has proven eﬃ  cacy,7,20 and to 
assess for superiority of the safety of reduced doses 
compared with placebo, in people with normal G6PD 
enzyme function.
Methods
Study design and participants
The study was a randomised, double-blind, placebo-
controlled trial with four parallel groups. The study 
protocol has been described in detail elsewhere.21 Brieﬂ y, 
we undertook the study at Walukuba Health Centre IV in 
Jinja district, eastern Uganda, between December, 2011, 
and March, 2013. In this region, malaria transmission is 
perennial with seasonal peaks in intensity. An 
entomological inoculation rate of seven infectious bites 
per person per year was estimated in 2001.22 
Eligible participants were children aged 1–10 years 
attending the health centre with fever or history of fever 
in the past 24 h, P falciparum monoinfection with a 
parasite density lower than 500 000 per μL, and normal 
G6PD enzyme function based on a ﬂ uorescence spot test 
(R&D Diagnostics, Aghia Paraskevi, Greece). Exclusion 
criteria were evidence of severe illness or danger signs, 
haemoglobin concentration less than 80 g/L, known 
allergy to the study drugs, antimalarials taken within the 
past 2 days, primaquine taken within the past 4 weeks, 
and blood transfusion within the past 90 days. Written 
informed consent was provided by parents or guardians 
and, in addition, assent was provided by children older 
than 8 years of age.
Ethics approval for the trial protocol and informed 
consent forms were provided by the Makerere University 
School of Medicine research ethics committee (protocol 
2011-210), the Uganda National Council of Science and 
Technology (protocol HS1056), and the London School of 
Hygiene and Tropical Medicine research ethics 
committee (protocol 5987). The Ugandan National Drug 
Authority approved importation of the study drug. The 
trial data safety monitoring board and trial advisory 
committee were convened before the start of the trial and 
met at predetermined stages of the study. Con sultations 
with local community stakeholders in Walukuba were 
held before, during, and after trial completion. 
Randomisation and masking
We randomly assigned eligible participants to one of four 
dose groups. In each group, we gave participants 
artemether–lumefantrine twice daily on days 0–2 and, with 
the ﬁ fth dose of the drug, one dose of either placebo or 
primaquine (0∙1 mg/kg, 0∙4 mg/kg, or 0∙75 mg/kg). A 
statistician at the London School of Hygiene and Tropical 
Medicine (ELW) computer-generated four-digit treatment 
assignment codes and allocated these to random dose 
groups in block sizes of 16. To achieve treatment 
concealment, we added masking syrup to all treatment 
groups, which disguised the colour and taste of the study 
drug. Because G6PD deﬁ ciency is an X chromosome-
linked disorder, we stratiﬁ ed random isation by sex. 
Sequential sealed envelopes con taining a randomisation 
code were selected by the study pharmacist from either the 
male or female pile. The pharmacist was not involved in 
patient outcome assessment. All other study staﬀ  providing 
care or assessing outcomes, and the participants 
themselves, remained masked to the intervention group 
after assignment. 
Procedures
We crushed 15 mg base primaquine phosphate tablets 
and dissolved them in 15 mL of drinking water to produce 
a stable 1 mg/mL solution. We drew up the assigned dose 
to the nearest 0∙5 mL through a sterile syringe and 
immediately gave it to each participant in a plastic cup or 
spoon. We administered all treatments after the children 
had eaten a fatty snack (biscuits) and then directly 
observed the patients. If a child vomited within 30 min, 
treatment was re-administered. Those who vomited 
more than three times were excluded from the study and 
were treated for complicated malaria.
Enrolled participants were reviewed on days 0, 1, 2, 3, 7, 
10, 14, 21, and 28, or on additional days if they presented 
at the clinic. We did systematic and prospective assess-
ments for adverse events. We graded new or worsening 
symptoms, examination ﬁ ndings, or laboratory ab -
normalities according to a severity scale (adapted from 
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the WHO toxicity grading scale for determining the 
severity of adverse events and from the National 
Institutes of Health, Division of Microbiology and 
Infectious Diseases paediatric toxicity tables published in 
January, 2003)23 and assessed causal associations with the 
study drug. We implemented a standardised protocol to 
detect episodes of haemolytic anaemia, which we have 
published elsewhere.21 On scheduled visits, we collected 
roughly 500 μL of venous blood for laboratory assess-
ments. On all visits, we did asexual malaria parasite 
counts, in which we enumerated parasites per 200 white 
blood cells; we read 100 microscopy ﬁ elds in the Giemsa-
stained thick blood ﬁ lm before we judged a slide to be 
parasite negative. At enrolment, we read slides twice 
speciﬁ cally for gametocytes, following the same 
procedure as that for asexual parasites. We measured 
haemoglobin con centration on days 0, 1, 2, 3, 7, 10, 14, 21, 
and 28 with self-calibrating HemoCue 201+ photometers 
(HemoCue; Angelholm, Sweden). We assessed gameto-
cytaemia by quantitative real-time nucleic acid sequence-
based analysis (QT-NASBA) with Pfs25 mRNA24 on days 
0, 2, 3, 7, 10, and 14. The timing of gametocytaemia 
measure ments was based on ﬁ ndings from previous 
studies that suggested the gametocyte-clearing eﬀ ect of 
primaquine is restricted to the ﬁ rst 2 weeks after 
treatment.7,25 We extracted nucleic acids from 50 μL blood 
samples in L6 buﬀ er (Severn Biotech Limited, 
Kidderminster, UK) with Total Nucleic Acid Isolation 
Kits–High Performance (Roche Applied Science, 
Mannheim, Germany) and a MagNA Pure LC automated 
extractor (Roche Applied Science). The sensitivity of this 
assay is related to the volume of blood sampled and is in 
the range of 0∙02–0∙1 gametocytes per μL for the samples 
collected.24
The primary endpoint for eﬃ  cacy was the non-
inferiority of the mean duration of gametocyte carriage 
in the test doses compared with the reference group of 
0∙75 mg primaquine base per kg. Secondary endpoints 
were the point prevalence of gametocytes on days 7, 10, 
and 14 after treatment, gametocyte circulation time, and 
the area under the curve (AUC) of gametocyte density 
over time after primaquine administration. For treatment 
outcomes in each group, deﬁ nitions of adequate clinical 
and parasitological response, early treatment failure, and 
late treatment failure were according to WHO Methods 
for Surveillance of Antimalarial Drug Eﬃ  cacy.26 The 
primary safety endpoint was the superiority of the 
arithmetic mean maximum decrease in haemoglobin 
concentration from enrolment to day 28 of follow-up in 
the primaquine treatment groups compared with the 
placebo group. Secondary safety endpoints were the 
superiority assessment of the day of haemoglobin nadir, 
the maximum percentage decrease in haemoglobin, 
the  percentage of participants with haemoglobin 
con centration lower than 50 g/L, requirement for blood 
transfusion, evidence of black urine, and the frequency 
of severe adverse events.
Statistical analysis
In our sample size calculation, we took into consideration 
the primary endpoints for both eﬃ  cacy and safety. To 
guide the eﬃ  cacy calculation, we used the QT-NASBA-
measured duration of gametocyte carriage in a Tanzanian 
study, which was reduced from a mean of 28∙6 to 6∙3 days 
(SD 6) when primaquine (0∙75 mg/kg) was added to ACT 
alone.25 Eﬃ  cacy analyses were done on an intention-to-
treat basis. To assess non-inferiority of the test groups to 
the reference group with 80% power at the two-tailed 5% 
signiﬁ cance level, with allowance for 10% loss to follow-
up and with use of a proposed clinically relevant non-
inferiority margin of 2∙5 days, the target sample size for 
eﬃ  cacy was 120 participants per group. However, during 
the course of review by the trial data safety monitoring 
board, the target sample size was reduced to 
460 participants (ie, 115 per group instead of 120) because 
of a lower than expected loss to follow-up. For the safety 
component of our analysis, the sample size calculation 
was based on the mean decrease in Hemocue-measured 
haemoglobin concentration on day 7 after treatment with 
primaquine of 6 g/L (SD 15) in a previous Tanzanian 
study.18 A sample size of 99 participants per group would 
provide 80% power to detect a diﬀ erence in mean 
maximum decrease in haemoglobin between treatment 
groups of 6 g/L at a signiﬁ cance level of 5%. 
Data were double entered and transferred into Stata 
(version 12.0) for analysis. We estimated duration of 
gametocyte carriage and gametocyte circulation time in 
children with gametocytaemia on day 2 (the day of 
primaquine dosing) with a straightforward deterministic 
compartmental mathematical model25 that allows for the 
release of gametocytes from sequestration and 
incorporates baseline gametocyte densities into model 
estimates. The model allows the duration of gametocyte 
carriage to be estimated as a continuous outcome. As the 
spacing between sampling times increases, some 
uncertainty is expected, but this was judged to be 
acceptable for estimates during the ﬁ rst 14 days after 
initiation of treatment. We compared treatment groups 
for non-inferiority to the reference group with two-sided 
95% CIs. Because the distribution of gametocyte densities 
was expected to be skewed, all density analyses involved 
log10-transformed data and we used geometric means as 
summary statistics. We assessed the AUC of gametocyte 
density per participant with the linear trapezoid method27 
and log10-transformed the data. We used ANOVA to 
compare log AUC with the reference treatment group. We 
compared gametocyte point prevalence estimates per 
treatment group with the reference group with use of the 
prevalence ratio with 95% CIs. We adjusted all eﬃ  cacy 
analyses for gametocyte density at enrolment, and tested 
the potential eﬀ ect of sex by adding this variable to 
multivariate models and by doing a stratiﬁ ed analysis.
The primary safety outcome, maximum decrease in 
haemoglobin (g/L) during follow-up compared with the 
measurement at enrolment, is expressed as an arithmetic 
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mean per treatment group and pairwise comparisons 
made between placebo and each of the primaquine 
groups, with unpaired t tests. We used a cutoﬀ  for 
signiﬁ cance tests of p=0·05 for the superiority analysis. 
We compared the occurrence of adverse events between 
groups; the signiﬁ cance level was adjusted for several 
comparisons by Bonferroni correction. This trial is 
registered with ClinicalTrials.gov, number NCT01365598.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study. All authors reviewed 
the report and agreed to submit for publication.
Results
We screened 1215 children with a history of fever and a 
positive blood smear at Walukuba Health Centre for 
eligibility to enrol in the study. The most frequent reason 
for exclusion was having taken antimalarial drugs in the 
previous 48 h (ﬁ gure 1). Between December, 2011, and 
December, 2012, we enrolled and randomly allocated 
468 children, 461 of whom completed treatment and 
contributed data for the assessment of safety and eﬃ  cacy 
(ﬁ gure 1).  36 of these 461 children (8%) did not complete 
28 day follow-up. The proportion lost to follow-up did not 
diﬀ er signiﬁ cantly between treatment groups, but was 
highest in the placebo group (ﬁ gure 1). Baseline 
characteristics were similar in all treatment groups 
(table 1). 199 of 461 (43%) children were anaemic at baseline 
(haemoglobin concentration <110 g/L). Treatment failure, 
assessed clinically and microscopically, was rare (table 2) 
and did not diﬀ er signiﬁ cantly between groups (p=0∙68). 
Gametocyte prevalence at enrolment was 22∙6% 
(104/461) by microscopy and 81∙8% (365/446) by 
QT-NASBA (table 1), and did not diﬀ er between treatment 
groups (p=0∙91 for microscopy and p=0∙42 for 
QT-NASBA). Gametocyte density at enrolment was 
numerically higher in the 0∙75 mg/kg reference group 
(table 1) but did not diﬀ er signiﬁ cantly from any of the 
other groups (p≥0∙31). Gametocyte prevalence decreased 
 468 randomly assigned
1215 patients assessed for eligibility
Randomisation
Initial screening
11 lost to follow-up
  0 withdrew consent
  2 excluded before day 3
 4 lost to follow-up 
  0 withdrew consent
117 received AL plus placebo 
 (ITT population)
119 allocated to AL plus placebo
102 completed safety follow-up
106 completed eﬃcacy follow-up
Study drug
Treatment 
allocation
28 day follow-up 
for safety
14 day follow-up 
for eﬃcacy
7 lost to follow-up
0 withdrew consent
1 excluded before day 3
0 lost to follow-up
0 withdrew consent
115 received AL plus PQ 0·1 mg/kg 
 (ITT population)
116 allocated to AL plus 
 PQ 0·1 mg/kg
108 completed safety follow-up
108 completed eﬃcacy follow-up
6 lost to follow-up
0 withdrew consent
3 excluded before day 3
1 lost to follow-up
0 withdrew consent
113 received AL plus PQ 0·4 mg/kg 
 (ITT population)
116 allocated to AL plus 
 PQ 0·4 mg/kg
106 completed safety follow-up
107 completed eﬃcacy follow-up
5 lost to follow-up
0 withdrew consent
1 excluded before day 3
0 lost to follow-up
0 withdrew consent
116 received AL plus PQ 0·75 mg/kg 
 (ITT population)
117 allocated to AL plus 
 PQ 0·75 mg/kg
111 completed safety follow-up
111 completed eﬃcacy follow-up
747 excluded 
 463 exclusion criteria
  5 serious chronic illness
  83 intented to leave study area
 154 took antimalarials 2 days earlier
  91 underweight
  7 severe malaria or danger signs
  31 low haemoglobin
  32 G6PD deﬁciency
  6 mixed infection
  17 hyperparasitaemia
  37 other (<5 per group)
  96 declined to participate 
 188 unaccompanied minors (ineligible)
Figure 1: Trial proﬁ le
AL was given as six doses over 3 days (days 0, 1, and 2); PQ or placebo was given together with the ﬁ fth dose of AL on the morning of day 2. The two post-treatment exclusions in the 0·4 mg/kg treament 
group (because of delayed conﬁ rmation of parasitaemia) were followed up for safety. G6PD=glucose-6-phosphate dehydrogenase. AL=artemether–lumefantrine. PQ=primaquine. ITT=intention to treat.
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after enrolment, although 170 of 345 (49∙3%) participants 
who were gametocyte positive at enrolment remained so 
on day 2 before receiving primaquine or placebo. After 
day 2, the rate of gametocyte clearance was dependent on 
treatment group. The mean duration of gametocyte 
carriage was 6∙6 days (95% CI 5∙3–7∙8) in the 0∙75 mg/kg 
reference group, 6∙3 days (5∙1–7∙5) in the 0∙4 mg/kg 
group, 8∙0 days (6∙6–9∙4) in the 0∙1 mg/kg group, and 
12∙4 days (9∙9–15∙0) in the placebo group (table 3).  The 
duration of gametocyte carriage for children who were 
gametocyte positive at primaquine administration was 
the primary outcome and was tested for non-inferiority 
to the 0·75 mg/kg reference group. With the proposed 
non-inferiority margin of 2∙5 days, the 0∙4 mg/kg group 
showed non-inferiority to the reference 0∙75 mg/kg 
group, but the 0∙1 mg/kg group was inconclusive for 
non-inferiority and placebo was inferior (ﬁ gure 2). 
The mean circulation time of gametocytes indicated a 
longer circulation time of gametocytes in the 0∙1 mg/kg 
group (p=0∙0012) and the placebo group (p<0∙0001) than 
Placebo (n=117) Primaquine 0·1 mg/kg 
(n=115)
Primaquine 0·4 mg/kg 
(n=113)
Primaquine 0·75 mg/kg 
(n=116)
Boys 48·7% (57/117) 49·6% (57/115) 49·6% (56/113) 49·1% (57/116)
Age (years) 5·0 (3·0–7·5) 5·0 (3·3–7·0) 5·3 (3·2–7·0) 4·1 (3·0–7·0)
Bodyweight (kg) 16·0 (13·0–20·5) 16·0 (13·0–22·0) 17·0 (14·0–23·0) 15·0 (13·0–19·0)
Body temperature (°C) 38·0 (1·0) 38·3 (1·1) 38·0 (1·2) 38·2 (1·1)
Haemoglobin concentration (g/L) 113 (15) 109 (15) 112 (15) 112 (14)
Geometric mean sexual parasite density,  
parasites/mL (IQR)
17 661 (5260–65 130) 18 420 (4440–92 780) 16 457 (3260–81 240) 32 497 (10 880–151 180)
Gametocyte prevalence by microscopy 23·1% (27/117) 24·3% (28/115) 20·4% (23/113) 22·4% (26/116)
Gametocyte prevalence by QT-NASBA 79·8% (91/114) 86·7% (98/113) 78·7% (85/108) 82·0% (91/111)
Geometric mean gametocyte density 
(gametocytes/μL) by QT-NASBA (IQR) 
15·2 (8·4–27·8) 14·5 (8·9–23·5) 19·4 (11·3–33·1) 24·6 (14·9–40·5)
Data are % (n/N), median (IQR), or mean (SD), unless otherwise indicated. QT-NASBA=quantitative real-time nucleic acid sequence-based analysis.
Table 1: Baseline characteristics
Placebo Primaquine 
0·1 mg/kg
p value* Primaquine 
0·4 mg/kg
p value* Primaquine 
0·75 mg/kg
p value*
Number evaluated 117 115  ·· 113  ·· 116  ··
Excluded from ITT analysis
Withdrawal unrelated to study drug 
or malaria
0 0  ·· 2/113 (1·8%) 0·245 0  ··
Lost to follow-up 15/117 (12·8%) 7/115 (6·1%) 0·080 7/113 (6·2%)  0·088 5/116 (4·3%) 0·033
ACPR on day 28 98/102 (96·1%) 101/108 (93·5%) 0·41 106/106 (100%) 0·12 106/111 (95·5%) 0·83
Treatment failures
Early (day 3) 0 0 ·· 0 ·· 0 ··
Late (day 28) 4/102 (3·9%) 7/108 (6·5%) 0·41 0 0·12 5/111 (4·5%) 0·83
Data are n/N (%), unless otherwise indicated. ITT=intention to treat. ACPR=adequate clinical and parasitological response. Deﬁ nitions of ACPR, early treatment failure, and 
late treatment failure are according to WHO Methods for Surveillance of Antimalarial Drug Eﬃ  cacy 2009.26 *p values are for comparison with placebo, with χ² or Fisher’s exact 
tests. Outcomes are unadjusted by PCR.
Table 2: Treatment outcomes for the diﬀ erent regimens on day 28 after start of treatment 
Placebo p value* Primaquine 
0·1 mg/kg
p value* Primaquine 
0·4 mg/kg
p value* Primaquine 
0·75 mg/kg
Duration of gametocyte carriage (days)† 12·4 (9·9–15·0) <0·0001 8·0 (6·6–9·4) 0·14 6·3 (5·1–7·5) 0·74 6·6 (5·3–7·8)
Circulation time per gametocyte (days) 1·97 (1·64–2·31) <0·0001 1·47 (1·22–1·73) 0·0012 0·95 (0·77–1·13) 0·80 0·98 (0·78–1·18)
Gametocyte prevalence on day 7 40/115 (34·8%) 0·001 25/108 (23·1%) 0·044 11/104 (10·6%) 0·47 15/104 (14·4%)
Gametocyte prevalence on day 10 23/112 (20·5%) 0·008 18/107 (16·8%) 0·020 10/107 (9·3%) 0·46 8/108 (7·4%)
Gametocyte prevalence on day 14 16/105 (15·2%) 0·017 6/103 (5·8%) 0·72 3/103 (2·9%) 0·51 6/106 (5·7%)
Data are mean (95% CI) or n/N (%). Except for the duration of gametocyte carriage, all estimates were adjusted for gametocyte density at enrolment. *p values are for 
comparison with reference 0·75 mg/kg treatment group. †Calculated for all children who had gametocytes on the day of primaquine or placebo administration.
Table 3: Gametocyte carriage during follow-up for the diﬀ erent treatment regimens
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in the reference 0∙75 mg/kg group (table 3). Gametocyte 
circulation time did not diﬀ er signiﬁ cantly between the 
0∙4 mg/kg group and the reference 0∙75 mg/kg group 
(p=0∙80). Compared with the reference 0∙75 mg/kg 
group, gametocyte prevalence was signiﬁ cantly higher in 
the 0∙1 mg/kg group on days 7 and 10, and signiﬁ cantly 
higher in the placebo group on days 7, 10, and 14 (table 3). 
We recorded no diﬀ erence in prevalence between the 
0∙4 mg/kg group and the reference group throughout 
follow-up (table 3, ﬁ gure 3). The overall geometric mean 
gametocyte density was 17∙9 gametocytes per μL (95% CI 
13∙8–23∙3) at enrolment, 15∙7 gametocytes per μL 
(11∙0–22∙2) on day 2 before primaquine treatment, 
11∙6 gametocytes per μL (7∙2–18∙8) on day 3, 
5∙3 gametocytes per μL (3∙0–9∙3) on day 7, 
5∙2  gametocytes per μL (2∙6–10∙5) on day 10, and 
2∙1 gametocytes per μL (0∙7–5∙7) on day 14. This decrease 
in the density of gametocytes in gametocyte-positive 
people during follow-up was statistically signiﬁ cant 
(p<0∙0001) but densities in these patients did not diﬀ er 
signiﬁ cantly between treatment groups on discrete 
follow-up days (data not shown). 
The AUC of gametocyte density over time, a measure 
that incorporates both prevalence and density of QT-
NASBA estimates, was 3∙8 (95% CI 1∙7–8∙2) gametocytes 
per μL per day in the placebo group, 3∙8 (1∙8–7∙8) in the 
0∙1 mg/kg group, 2∙1 (1∙0–4∙5) in the 0∙4 mg/kg group, 
and 2∙0 (0∙9–4∙3) in the 0∙75 mg/kg group. After 
adjustment for gametocyte density at enrolment, the 
AUC compared with the reference group did not diﬀ er 
signiﬁ cantly for the 0∙4 mg/kg group (p=0∙79) or the 
placebo group (p=0·16), but was signiﬁ cantly higher in 
the 0∙1 mg/kg group (p=0∙043; data not shown). None of 
the eﬃ  cacy estimates were aﬀ ected by the sex of the 
participants (data not shown).
The mean maximum decrease in haemoglobin 
concentration did not diﬀ er signiﬁ cantly compared with 
placebo (10·7 g/L, SD 11·1) in the 0∙1 mg/kg (11·4 g/L, 
9·4; p=0∙61), 0∙4 mg/kg (11·3 g/L, 10·0; p=0∙67), or 
0∙75 mg/kg (12·7 g/L, 8·2; p=0∙11) groups. The size of 
the fall in haemoglobin concentration was not 
signiﬁ cantly associated with primaquine dose (p=0∙46). 
The timing of the nadir in haemoglobin was independent 
of treatment group, and the greatest contribution to the 
total decrease in haemoglobin occurred before day 2 
when the study drug was administered. By day 28, in all 
treatment groups, haemoglobin concentrations had 
recovered and exceeded baseline concentrations 
(ﬁ gure 4). We recorded no cases of black water fever; red, 
black, or tea-coloured urine; or severe haemolysis; and 
no child needed a blood transfusion. Sex had no eﬀ ect on 
safety outcomes (data not shown).
The proportion of participants having adverse events 
did not diﬀ er between treatment groups after adjustment 
of signiﬁ cance levels for multiple comparisons (data not 
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real-time nucleic acid sequence-based analysis gametocyte prevalence estimates. 
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(A) Gametocyte prevalence during follow-up, as measured by Pfs25 quantitative real-time nucleic acid 
sequence-based analysis. Error bars indicate the upper limit of the 95% CI. (B) Odds ratio of gametocyte prevalence 
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shown). In the sex-stratiﬁ ed analysis, the maximum 
reduction in haemoglobin concentration seemed to be 
larger in the 0·75 mg/kg group compared with the 
placebo group in girls (p=0·023), but this diﬀ erence was 
not statistically signiﬁ cant after correction for multiple 
comparisons (Bonferroni threshold level for signiﬁ cance 
p=0·0083). One child, aged 1·5 years, had a haemoglobin 
concentration of less than 50 g/L, which was the only 
severe adverse event. This boy, who received 0∙4 mg/kg 
primaquine, had a baseline haemoglobin concentration 
of 99 g/L. On day 9 of follow-up, he underwent an elective 
surgical procedure in a mobile clinic. The mother 
reported no attempt at haemostasis postoperatively and 
the child had bled severely. By day 14, his haemoglobin 
concentration had fallen to 49 g/L without clinical 
compromise. After wound care and treatment with iron 
and folate, his haemoglobin concentration recovered to 
106 g/L on day 28. This event was judged to be unrelated 
to the study drug.
Discussion
This study is the ﬁ rst formal dose-ﬁ nding trial to assess 
P falciparum gametocyte clearance after treatment with 
single-dose primaquine when given in combination with 
an ACT (panel). We showed that the duration of 
gametocyte carriage was roughly halved when 0∙75 mg 
primaquine per kg was given in addition to ACTs. A 
reduced dose of 0∙4 mg/kg had a non-inferior 
gametocytocidal eﬀ ect compared with the WHO 
reference dose, whereas the duration of gametocyte 
carriage was inconclusive for non-inferiority in the 
0∙1 mg/kg group and gametocyte prevalence was higher 
during follow-up than at baseline. Safety outcomes did 
not diﬀ er signiﬁ cantly between the treatment groups.
In this population of children with uncomplicated 
clinical malaria, gametocytes were detected at baseline in 
a quarter  of children by microscopy compared with four-
ﬁ fths by molecular methods, which is consistent with 
previous ﬁ ndings and emphasises the inadequate 
sensitivity of microscopy in identiﬁ cation of potentially 
infectious people.31 Gametocyte prevalence decreased 
during follow-up; roughly half of the patients with 
gametocytes at enrolment cleared their gametocytes 
during the ﬁ rst 2 days of treatment, before primaquine 
was given. These dynamics diﬀ er from those reported in 
children in a previous ACT–primaquine trial that showed 
a more gradual reduction in gametocyte prevalence after 
ACT,7 but are similar to those recorded in symptomatic 
Kenyan children of the same age group.3 Although 
primaquine shortened the duration of gametocyte 
carriage, we noted that even the highest single dose of the 
drug did not render all participants gametocyte negative. 
In previous studies in Burma and Indonesia, microscopic 
gametocytes persisted in a few individuals 21 days after 
primaquine treatment.8,9 In our study, six of 106 (5·7%) 
children were gametocyte positive by molecular methods 
on day 14 after initiation of treatment, even with the 
highest dose of primaquine. However, the density of 
these persistent gametocytes was much lower than that at 
enrolment. We used gametocyte density estimates for 
secondary outcome measures because no clear lower 
threshold gametocyte density that is needed for successful 
mosquito infection has been established.32–34 The 
gametocyte circulation time, which was calculated on the 
basis of the rate of decrease of gametocyte densities after 
treatment, was signiﬁ cantly longer in the placebo and 
0∙1 mg/kg groups than in the reference group, but did 
not diﬀ er signiﬁ cantly between the 0∙4 mg/kg group and 
the reference 0∙75 mg/kg group. The AUC of gametocyte 
density over time, a summary measure for malaria 
transmission potential,7,27,35 was numerically higher in the 
placebo group and 0∙1 mg/kg dose group than in the 
0∙75 mg/kg dose group, but this diﬀ erence was 
statistically signiﬁ cant only for the 0∙1 mg/kg dose group. 
There was no siginﬁ cant diﬀ erence in the AUC between 
the 0∙4 mg/kg and the 0∙75 mg/kg dose  groups. Baseline 
diﬀ erences in asexual parasites between treatment groups 
did not result in diﬀ erences in baseline gametocyte 
prevalence or density or diﬀ erences in treatment 
outcome, and did not confound the comparison of 
gametocyte dynamics between groups.
Although we used sensitive molecular gametocyte 
detection methods in our trial and therefore provide detail 
that is absent from most other primaquine trials, a relevant 
shortcoming of this and other studies is that gametocyte 
infectiousness to mosquitoes was not established. A 
proportion of the gametocytes that are observed by 
microscopy shortly after primaquine treatment might be 
non-infectious.15 Whether or not Pfs25 mRNA can be 
detected from non-viable gametocytes is unknown, and a 
proportion of the gametocytes that we detected could have 
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been non-infectious. We might, therefore, have under-
estimated the transmission-blocking eﬀ ect of primaquine. 
None of the available gametocyte detection devices allow 
inferences to be made about the infectiousness of 
gametocytes to mosquitoes, and only mosquito feeding 
assays can provide deﬁ nitive evidence for the trans-
missibility of gametocytes. However, limitations do exist in 
the extent to which labour-intensive mosquito feeding 
assays can be used in clinical trials.36 Although gametocyte 
measurements can be done repeatedly from the same 
patient, the few clinical trials that have used mosquito 
feeding assays typically do feeding experiments at one 
timepoint per participant3,37,38 and thereby ignore the 
dynamics of gametocyte infectivity.38 Future studies that 
investigate the gametocytocidal eﬀ ects of low-dose 
primaquine should therefore preferentially include 
mosquito feeding assays at intervals during follow-up. 
A further limitation of this study was the absence of 
available paediatric dose formulations for primaquine, 
which necessitated titration of crushed primaquine in 
solution for accurate dosing. Although crushed tablets 
have been used previously for the 0∙75 mg/kg dose,7,8 
this approach might have aﬀ ected eﬃ  cacy, especially of 
the lowest dose (0∙1 mg/kg). More data for the relative 
bioavailability of diﬀ erent formulations of primaquine 
are needed. Hence, a prerequisite to the scaling up of 
primaquine deployment will be the availability of 
reliable paediatric formulations for low doses of the 
drug.
This study aimed to establish the eﬃ  cacy and safety of 
low-dose primaquine in people with normal G6PD 
enzyme function. G6PD-deﬁ cient children were 
excluded from this study based on the ﬂ uorescent spot 
test, the most widely used enzyme function test13 that 
detects enzyme function to a cutoﬀ  of about 20–30% of 
normal activity.39 We decided to exclude G6PD-deﬁ cient 
children so that we could ﬁ rst establish the lowest 
eﬃ  cacious dose before vulnerable patients are exposed 
to a potentially haemolytic drug. Although haemolysis 
has been reported in people without common mutations 
in the G6PD enzyme,29 the exclusion of those with 
abnormal enzyme function does clearly limit the 
generalisability of the safety outcomes of this study and 
this issue needs to be addressed in future studies. Given 
this caveat, haemoglobin concentrations fell most 
rapidly in the ﬁ rst 2 days after enrolment in all study 
groups, which implies that the greatest eﬀ ect on 
haemoglobin was caused by clinical malaria rather than 
a drug eﬀ ect. Thereafter, haemoglobin recovered to 
premorbid concentrations. A similar trend has been 
recorded in children in Tanzania,7 and in populations in 
Burma30 and Indonesia.9 We recorded no children with 
objective measures of clinically signiﬁ cant haemolysis 
or black urine, or who needed hospital admission or 
blood transfusion. The only severe adverse event was in 
a child who underwent an elective surgical procedure 
unrelated to the clinical malaria episode on day 9 and 
therefore after the expected duration of primaquine-
associated haemolysis.
In this dose-ﬁ nding trial, primaquine administration 
was delayed until day 2 after initiation of schizonticidal 
therapy. This timepoint is when, in the context of 
uncomplicated malaria, the rate of malaria-attributable 
haemolysis is expected to be falling, and comparisons of 
haematological eﬀ ects between dose groups are expected 
to be less aﬀ ected by the consequences of acute malaria 
infection. In operational terms, administration of 
primaquine on the ﬁ rst day of schizonticidal treatment is 
probably advantageous, and comparisons of the eﬃ  cacy 
of day 0 versus day 2 administration will be important. 
For more than 40 years, WHO has recommended a 
single dose of 0∙75 mg primaquine base per kg in 
Panel: Research in context
Systematic review
We searched PubMed on May 25, 2013, without date or language restrictions, with the 
terms “primaquine” and “malaria, falciparum” and “gametocyte” or “primaquine” and 
“malaria, falciparum” and “transmission”. We identiﬁ ed no randomised controlled trials 
assessing the dose-response relation of primaquine for gametocytocidal activity. 
A Cochrane review of the transmission-reducing eﬃ  cacy of primaquine published in 
September, 2012, identiﬁ ed ﬁ ve trials assessing a primaquine–artemisinin combination 
therapy combination that satisﬁ ed the criteria for inclusion and none of these analysed a 
range of doses.28 Three studies have assessed the haematological safety of primaquine with 
artemisinin combination therapies,7,29,30 but our trial is unique in that it was speciﬁ cally 
powered to assess safety outcomes. A search of clinical trial registration sites for 
primaquine dose-ﬁ nding trials for transmission blocking showed one trial that is 
underway in The Gambia (NCT01838902) to assess the eﬃ  cacy of artemisinin 
combination therapy alone, and with 0·2 mg/kg, 0·4 mg/kg, or 0·75 mg/kg primaquine 
base in asymptomatic patients. This trial is scheduled for completion in 2015. Another 
study (NCT01743820), which is in development, will assess primaquine dose escalation 
from 0·125 mg/kg in 50 participants randomly allocated to diﬀ erent dosing groups. 
Several other registered studies with primaquine for Plasmodium  falciparum do not 
involve dose-ﬁ nding but will address relevant questions for the future wide-scale 
deployment of primaquine. These studies include a trial of the optimum timing of 
primaquine administration (NCT01906788, recruiting), primaquine pharmacokinetics 
(NCT01552330 and NCT01525511, both completed August, 2013), and a trial with 
mosquito feeding as an endpoint that will compare artemisinin combination therapy 
alone with 0·75 mg/kg primaquine (NCT01849640, not yet recruiting, with a scheduled 
3-year timeline).
Interpretation
This study is, to our knowledge, the ﬁ rst randomised, placebo-controlled trial to assess the 
dose-response relation of one dose of primaquine for gametocyte clearance and for safety 
in falciparum malaria. This trial was undertaken in African children with clinical malaria and 
normal glucose-6-phosphate dehydrogenase enzyme function. A dose reduction to 
0·4 mg/kg primaquine base had demonstrable non-inferiority to the reference 0·75 mg/kg 
dose, whereas a dose of 0·1 mg/kg was inconclusive for non-inferiority. This trial was 
designed and started before a revision of the WHO guidelines recommending 0·25 mg/kg 
primaquine for transmission blocking, in light of which this new dose must now be 
assessed. In this population, all doses of primaquine had similar safety proﬁ les to placebo. 
An study of low-dose primaquine in people with glucose-6-phosphate dehydrogenase 
deﬁ ciency is warranted. 
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combination with schizonticidal drugs to reduce trans-
mission of malaria.40 However, no dose-ﬁ nding trials 
underpinned this recommendation. The small evidence 
base for primaquine use has prompted uncertainty as 
to the beneﬁ t of an intervention that carries a 
documented risk of haemolysis in malaria-endemic 
populations.28,41 The real threat of spreading artemisinin 
resistance42 has led to urgency in addressing this 
problem. In September, 2012, while our study was 
ongoing, an evidence review group commissioned by 
WHO revised its recommended dose to 0∙25 mg 
primaquine base per kg to be added to ACT to treat 
parasitologically conﬁ rmed falciparum malaria 
infection in new programmes for malaria elimination 
and to stop the spread of artemisinin resistance.43 This 
dose revision was based on underpowered historical 
studies, and the need for contemporary data was 
emphasised.44 The 0∙25 mg/kg dose was not assessed 
in our study, which is a limitation and leaves important 
questions to be addressed in future dose-ﬁ nding trials. 
However, we have shown that gametocytocidal eﬃ  cacy 
is retained when the primaquine dose is reduced from 
0∙75 mg/kg to 0∙4 mg/kg and that a dose-response 
relation exists for lower doses. The ﬁ nding of reduced 
gametocytocidal eﬃ  cacy at doses lower than 0∙4 mg/kg 
seems to contradict suggestions of uniform eﬃ  cacy in 
the range of 0∙065–0∙75 mg primaquine per kg.16 This 
new information provides a valuable starting point for 
identiﬁ cation of the most eﬃ  cacious and safest low 
dose of primaquine for transmission blocking. 
Subsequent investigations of primaquine should 
include assess ments of the eﬃ  cacy of doses lower than 
0∙4 mg/kg (including the newly recommended 
0∙25 mg/kg dose), with use of mosquito transmission 
endpoints to allow for diﬀ erences in infectiousness of 
gametocytes persisting after treatment; the optimum 
timing of primaquine in combination with ACT;  the 
pharmacokinetics of low-dose primaquine; and the 
safety of low-dose primaquine in people with G6PD 
enzyme deﬁ ciency, which is of high priority. Because of 
diﬀ erences in gametocyte dynamics between African 
and Asian settings45 and diﬀ erences in the severity of 
G6PD deﬁ ciency across regions,46 studies in a range of 
malaria-endemic settings are needed.
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